# OnCo record nct06885034 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06885034/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06885034", "NCT06885034" ;
  schema:name "A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)"@en ;
  schema:alternateName "EMBOLD PanGI-201"@en ;
  schema:description "A phase 1/2 trial of Risvutatug Rezetecan in advanced solid tumours, run by GlaxoSmithKline, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06885034/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06885034> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-06-11" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:companies <https://onco.cc/companies/gsk/> .